Effects of direct lung dosing of Tobramycin in a rat chronic infection model using Pseudomonas aeruginosa RP73

S. Gandi (Edinburgh, United Kingdom), I. Cranston (Edinburgh, United Kingdom), G. Mclachlan (Edinburgh, United Kingdom), S. Wright (Edinburgh, United Kingdom), J. Baily (Edinburgh, United Kingdom), S. Stimpson (Saffron Walden, United Kingdom), S. Madden (Edinburgh, United Kingdom), M. Whitmarsh (Harlow, United Kingdom), A. Young (Harlow, United Kingdom), M. Mcelroy (Edinburgh, United Kingdom)

Source: International Congress 2018 – Mechanisms of respiratory infection
Session: Mechanisms of respiratory infection
Session type: Thematic Poster
Number: 2656
Disease area: Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Gandi (Edinburgh, United Kingdom), I. Cranston (Edinburgh, United Kingdom), G. Mclachlan (Edinburgh, United Kingdom), S. Wright (Edinburgh, United Kingdom), J. Baily (Edinburgh, United Kingdom), S. Stimpson (Saffron Walden, United Kingdom), S. Madden (Edinburgh, United Kingdom), M. Whitmarsh (Harlow, United Kingdom), A. Young (Harlow, United Kingdom), M. Mcelroy (Edinburgh, United Kingdom). Effects of direct lung dosing of Tobramycin in a rat chronic infection model using Pseudomonas aeruginosa RP73. 2656

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The effect of erythromycin on the chronic lower airway infection by pseudomonas aeruginosa
Source: Eur Respir J 2004; 24: Suppl. 48, 640s
Year: 2004

Inhaled phage therapy for the treatment of acute Pseudomonas aeruginosa lung infections
Source: International Congress 2018 – Mechanisms of respiratory infection
Year: 2018

Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model
Source: Eur Respir J 2007; 29: 965-968
Year: 2007



Antibiotic efficacy varies based on the infection model and treatment regimen for Pseudomonas aeruginosa
Source: Eur Respir J, 55 (3) 1802456; 10.1183/13993003.02456-2018
Year: 2020



Exploring the susceptibility of P. aeruginosa biofilms in human mucus towards tobramycin treatment
Source: International Congress 2017 – Cystic fibrosis: clinical issues
Year: 2017

Comparison between two protocols of preventing treatment of chronic Pseudomonas aeruginosa (Pa) infection
Source: Eur Respir J 2005; 26: Suppl. 49, 620s
Year: 2005

Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection
Source: Eur Respir J 2005; 26: Suppl. 49, 620s
Year: 2005

Predicting the outcome of respiratory Pseudomonas aeruginosa infection in vivo
Source: International Congress 2017 – Cystic fibrosis: treatments and monitoring
Year: 2017

Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre
Source: Eur Respir J 2006; 27: 937-943
Year: 2006



Effects of erythromycin on Pseudomonas aeruginosa adherence to collagen and morphology in vitro
Source: Eur Respir J 2003; 21: 401-406
Year: 2003



Persistence and genetic adaptation of Pseudomonas aeruginosa in patients with COPD.
Source: Virtual Congress 2020 – Airway infection: the microbiome and beyond
Year: 2020




Novel swine ARDS model induced by Pseudomonas aeruginosa pneumonia and VILI
Source: Virtual Congress 2020 – Experimental and laboratory studies in intensive care unit medicine
Year: 2020


Therapeutic intratracheal phage application against Acinetobacter baumannii lung infection in mice
Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies
Year: 2018



The effect of clarithromycin on immunity of mice with chronic respiratory infection caused by P. aeruginosa
Source: Annual Congress 2008 - Aetiology of respiratory infections: mycobacteria and fungi
Year: 2008


Inhaled corticosteroid use and its association with Pseudomonas aeruginosa infection in COPD
Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies
Year: 2021


The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis
Source: Eur Respir J 2006; 28: 974-979
Year: 2006



In vitro activity of colistin in combination with N-acetylcysteine against Pseudomonas aeruginosa
Source: International Congress 2018 – Cystic fibrosis in paediatric patients: current research
Year: 2018

Variability of ß-lactamase resistance Pseudomonas aeruginosa genes infecting patients with cystic fibrosis
Source: Virtual Congress 2021 – Back to infection basics
Year: 2021


Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis
Source: Eur Respir J , 49 (4)  1600851; DOI: 10.1183/13993003.00851-2016
Year: 2017